Eleni Efstathiou is a Professor of Cancer Medicine and Chief of the Genitourinary Medical Oncology section at the Houston Methodist Cancer Center. She is internationally known for her breakthrough translational research in prostate cancer. One of the few physicians with practices on both sides of the Atlantic, she has extensive experience across the spectrum of genitourinary (GU) medical oncology.
Her goal is to combine the advantages of academic research with those of precision care thus offering the best possible care and treatment planning to patients, while promoting advances in therapeutics and community practice education. She has also established and directs a state-of-the-art GU Medical Oncology clinic affiliated to the MD Anderson Cancer Center within the Athens Medical Centre.
Dr Efstathiou’s main research has been novel androgen signalling inhibition treatment as a tool to guide marker-driven treatment strategies in prostate cancer, and genomic and non-genomic pathways of resistance.
Over the past 10 years, Dr Efstathiou has developed two major clinical trial platforms in the bone metastatic setting and locally advanced disease setting and has been performing “companion” studies exploring the impact of novel therapeutic agents on the tumour microenvironment and association with pre-treatment molecular characteristics. She is currently testing and validating proposed predictive signatures and is the Principal Investigator (PI; for biomarkers) for two large phase 3 trials testing the advantage of combinatorial androgen signalling inhibition in advanced prostatic carcinoma. She has also engaged in multiple collaborations outside her current institution worldwide.
Dr Efstathiou is the recipient of the Young Investigator Award and a Career Development Award awarded by the Prostate Cancer Foundation (PCF) and a PI / co-PI on PCF Challenge Awards. She is a European Society of Medical Oncology (ESMO) Academy faculty member and a founding and scientific committee member of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC). She has published more than 150 manuscripts in peer-reviewed journals. Of note, she is the only physician scientist to present her work orally at nine consecutive American Society of Clinical Oncology (ASCO) annual meetings. She also serves as the Chair of the GU Prostate Track Scientific Committee for ESMO 2021 and remains an ESMO committee member since the past 10 years.
Being among the first physician scientists to engage in prospective prostate cancer tissue–based and derivatives research studies and in identifying candidate pathways of resistance and feedback to novel treatments, she is an international expert spearheading therapy development strategy in prostate cancer.
EM-73536 - Date of preparation: September 2021